Taysha Gene Therapies logo

Taysha Gene Therapies Share Price (NASDAQ: TSHA)

$2.85

▲

0.02

(0.71%)

Live

Last updated on

Check the interactive Taysha Gene Therapies Stock chart to analyse performance

Taysha Gene Therapies stock performance

as on August 30, 2025 at 12:41 am IST

  • Today's Low:$2.79
    Today's High:$2.88

    Day's Volatility :3.12%

  • 52 Weeks Low:$1.05
    52 Weeks High:$3.31

    52 Weeks Volatility :68.28%

Taysha Gene Therapies Stock Returns

PeriodTaysha Gene Therapies IncSector (Health Care)Index (Russel 2000)
3 Months
4.06%
3.1%
0.0%
6 Months
76.25%
-8.4%
0.0%
1 Year
31.16%
-12.6%
0.0%
3 Years
-8.14%
7.9%
-6.1%

Taysha Gene Therapies Inc Key Stats

Check Taysha Gene Therapies key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$2.83
Open
$2.985
Today's High
$2.88
Today's Low
$2.79
Market Capitalization
$810.2M
Today's Volume
$1.8M
52 Week High
$3.31
52 Week Low
$1.05
Revenue TTM
$8.1M
EBITDA
$-88.0M
Earnings Per Share (EPS)
$-0.34
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-51.86%

Stock Returns calculator for Taysha Gene Therapies Stock including INR - Dollar returns

The Taysha Gene Therapies stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Taysha Gene Therapies investment value today

Current value as on today

₹1,37,735

Returns

₹37,735

(+37.74%)

Returns from Taysha Gene Therapies Stock

₹32,558 (+32.56%)

Dollar Returns*

₹5,177 (+5.18%)

Indian investors sentiment towards Taysha Gene Therapies Stock

-43%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Taysha Gene Therapies Stock from India on INDmoney has decreased by -43% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Taysha Gene Therapies Inc

  • Name

    Holdings %

  • RTW INVESTMENTS, LLC

    9.17%

  • RA Capital Management, LLC

    8.64%

  • venBio Select Advisor LLC

    7.96%

  • Morgan Stanley - Brokerage Accounts

    6.18%

  • FMR Inc

    5.73%

  • BlackRock Inc

    4.98%

Analyst Recommendation on Taysha Gene Therapies Stock

Rating
Trend

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 16 Wall street analysts offering stock ratings for Taysha Gene Therapies(by analysts ranked 0 to 5 stars)

Taysha Gene Therapies Share Price Target

What analysts predicted

Upside of 204.09%

Target:

$8.67

Current:

$2.85

Taysha Gene Therapies share price target is $8.67, a slight Upside of 204.09% compared to current price of $2.85 as per analysts' prediction.

Taysha Gene Therapies Stock Insights

  • Price Movement

    In the last 7 days, TSHA stock has moved down by -6.0%

  • TSHA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 57.5% return, outperforming this stock by 26.3%

  • TSHA vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.3% return, outperforming this stock by 127.1%

  • Price to Sales

    ForTSHA every $1 of sales, investors are willing to pay $97.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.8 for every $1 of sales.

Taysha Gene Therapies Technicals Summary

Sell

Neutral

Buy

Taysha Gene Therapies is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Taysha Gene Therapies Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Taysha Gene Therapies Inc logo
Taysha Gene Therapies Inc
2.92%
76.25%
31.16%
-8.14%
-88.28%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
3.77%
-17.64%
-51.18%
-2.19%
-7.17%
Beone Medicines Ltd logo
Beone Medicines Ltd
-0.02%
10.33%
51.07%
81.16%
24.14%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
-16.39%
-18.24%
-20.49%
39.42%
40.54%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
33.05%
83.22%
57.52%
115.32%
240.85%

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Organization
Taysha Gene Therapies
Employees
73
CEO
Mr. Sean P. Nolan
Industry
Health Technology

Key Management of Taysha Gene Therapies Inc

NameTitle
Mr. Sean P. Nolan
CEO & Chairman
Dr. Sukumar Nagendran M.D.
President, Head of Research & Development and Director
Mr. Kamran Alam CPA, M.B.A.
CFO & Corporate Secretary
Hayleigh Collins
Director of Corporate Communications & Investor Relations
Ms. Tracy M. Porter SPHR
Chief People Officer
Mr. Frederick Porter Ph.D.
Chief of Staff & Technical Operations Officer
Ms. Emily McGinnis M.P.H.
Chief Patient & External Affairs Officer
Mr. Sean McAuliffe
Chief Business Officer
Dr. Steven Gray Ph.D.
Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Berge Minassian M.D.
Chief Medical Advisor of UT Southwestern Gene Therapy Program

Important FAQs about investing in TSHA Stock from India :

What is Taysha Gene Therapies share price today?

Taysha Gene Therapies share price today is $2.85 as on . Taysha Gene Therapies share today touched a day high of $2.88 and a low of $2.79.

What is the 52 week high and 52 week low for Taysha Gene Therapies share?

Taysha Gene Therapies share touched a 52 week high of $3.31 and a 52 week low of $1.05. Taysha Gene Therapies stock price today i.e. is trending at $2.85, lower by 13.9% versus the 52 week high.

How to invest in Taysha Gene Therapies Stock (TSHA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Taysha Gene Therapies on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Taysha Gene Therapies Shares that will get you 0.5263 shares as per Taysha Gene Therapies share price of $2.85 per share as on August 30, 2025 at 12:41 am IST.

What is the minimum amount required to buy Taysha Gene Therapies Stock (TSHA) from India?

Indian investors can start investing in Taysha Gene Therapies (TSHA) shares with as little as ₹88.167 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.67 in Taysha Gene Therapies stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Taysha Gene Therapies share’s latest price of $2.85 as on August 30, 2025 at 12:41 am IST, you will get 3.5088 shares of Taysha Gene Therapies. Learn more about fractional shares .

What are the returns that Taysha Gene Therapies has given to Indian investors in the last 5 years?

Taysha Gene Therapies stock has given -88.28% share price returns and 20.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?